Humanized anti clever-1 antibodies and their use
AssigneeFaron Pharmaceuticals Oy
InventorsMikael MAKSIMOW, Markku JALKANEN, Marita VAINIO
Life of this patent
Estimating the term…
Abstract
This invention relates to an agent and a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 recognizing an epitope of CLEVER-1, wherein the epitope is discontinuous and comprises the sequences: PFTVLVPSVSSFSSR and QEITVTFNQFTK. This invention relates also an agent capable of binding to an epitope of human CLEVER-1 for use in removing tumour or antigen induced immunosuppression. Further, the invention relates to a pharmaceutical composition comprising the agent capable of binding to human CLEVER-1 and an appropriate excipient.
Claims22
An agent capable of binding to an epitope of human CLEVER-1, wherein the epitope is discontinuous and comprises the sequences:
- (SEQ ID NO:
- 1)
- PFTVLVPSVSSFSSR,
- and
- (SEQ ID NO:
- 2)
- QEITVTFNQFTK,
- and the agent comprises sequences of complementarity determining regions (CDRs) binding to said epitope sequences selected from the group consisting of
- (SEQ ID NO:
- 7)
- TSGMGIG,
- (SEQ ID NO:
- 8)
- HIWWDDDKRYNPALKS,
- (SEQ ID NO:
- 9)
- HYGYDPYYAMDY,
- (SEQ ID NO:
- 10)
- TASSSVSSSYLH,
- (SEQ ID NO:
- 11)
- RTSNLAS,
- and
- (SEQ ID NO:
- 12)
- HQYHRSPPT.
The agent capable of binding to human CLEVER-1 according to any of the preceding claims, wherein the agent is selected from the group consisting of an antibody, single chain Fv or Fab fragment(s), peptide(s) or macromolecule having an adequate affinity to bind to said epitope.
A humanized antibody or single chain Fv or Fab fragment capable of binding to an epitope of human CLEVER-1, wherein the epitope is discontinuous and comprises the sequences:
- (SEQ ID NO:
- 1)
- PFTVLVPSVSSFSSR,
- and
- (SEQ ID NO:
- 2)
- QEITVTFNQFTK,
- said antibody or single chain Fv or Fab fragment comprises
- a) constant regions of human IgG4 heavy chain and kappa light chain, and
- b) one or more of the following sequences of complementarity determining regions (CDRs)
- i) of the heavy chain
- CDR 1:
- (SEQ ID NO:
- 7)
- TSGMGIG,
- and/or
- CDR 2:
- (SEQ ID NO:
- 8)
- HIWWDDDKRYNPALKS,
- and/or
- CDR 3:
- (SEQ ID NO:
- 9)
- HYGYDPYYAMDY;
- and
- ii) of the light chain
- CDR 1:
- (SEQ ID NO:
- 10)
- TASSSVSSSYLH,
- and/or
- CDR 2:
- (SEQ ID NO:
- 11)
- RTSNLAS,
- and/or
- CDR 3:
- (SEQ ID NO:
- 12)
- HQYHRSPPT.
An agent capable of binding to human CLEVER-1 in an individual for use in removing tumour or antigen induced immunosuppression by modulating M2 macrophages into M1 macrophages, wherein the agent binds to an epitope of human CLEVER-1, which epitope is discontinuous and comprises the sequences:
- (SEQ ID NO:
- 1)
- PFTVLVPSVSSFSSR,
- and
- (SEQ ID NO:
- 2)
- QEITVTFNQFTK.
Dependencies are inferred from the claim text.